About Transmembrane protein 132E
Transmembrane protein 132E (TMEM132E) is a protein
from Homo sapiens identified by UniProt accession
Q6IEE7, 1074 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Target properties
| Protein name | Transmembrane protein 132E |
|---|
| UniProt accession | Q6IEE7 |
|---|
| Gene | TMEM132E |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1074 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (25)
Diseases linked to this target (Open Targets).
- hearing loss, autosomal recessive · score 0.56
- protein measurement · score 0.35
- age at first sexual intercourse measurement · score 0.26
- insomnia · score 0.24
- total blood protein measurement · score 0.23
- attention deficit hyperactivity disorder · score 0.23
- substance abuse · score 0.23
- antisocial behaviour measurement · score 0.23
- metabolite measurement · score 0.18
- PHF-tau measurement · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q6IEE7-F1 | alphafold | PREDICTED | 71.58 | — |
Amino-acid sequence (1074 residues)
MAPGMSGRGG AALLCLSALL AHASGRSHPA SPSPPGPQAS PVLPVSYRLS HTRLAFFLRE ARPPSPAVAN SSLQRSEPFV VFQTKELPVL NVSLGPFSTS QVVARELLQP SSTLDIPERL TVNWKVRAFI VRSHVPASQP VVQVLFYVAG RDWDDFGVTE RLPCVRLHAF RDAREVKSSC RLSGGLATCL VRAELPLAWF GPPAPAAPPT ARRKSPDGLE PEATGESQQA ELYYTLHAPD ASGGCGGSRR GAGPGVGARA ESPTQHPLLR IGSISLFRPP PRRTLQEHRL DSNLMIRLPD RPLKPGEVLS ILLYLAPNSS SPSSPSVEHF TLRVKAKKGV TLLGTKSRSG QWHVTSELLT GAKHSTATVD VAWAQSTPLP PREGQGPLEI LQLDFEMENF TSQSVKRRIM WHIDYRGHGA LPDLERAVTE LTVIQRDVQA ILPLAMDTEI INTAILTGRT VAIPVKVIAI EVNGLVLDIS ALVECESDNE DIIKVSSSCD YVFVSGKESR GSMNARVTFR YDVLNAPLEM TVWVPKLPLH IELSDARLSQ VKGWRVPILP DRRSVRESED EDEEEEERRQ SASRGCTLQY QHATLQVFTQ FHTTSSEGTD QVVTMLGPDW LVEVTDLVSD FMRVGDPRVA HMVDSSTLAG LEPGTTPFKV VSPLTEAVLG ETLLTVTEEK VSITQLQAQV VASLALSLRP SPGSSHTILA TTAAQQTLSF LKQEALLSLW LSYSDGTTAP LSLYSPRDYG LLVSSLDEHV ATVTQDRAFP LVVAEAEGSG ELLRAELTIA ESCQKTKRKS VLATTPVGLR VHFGRDEEDP TYDYPGPSQP GPGGGEDEAR GAGPPGSALP APEAPGPGTA SPVVPPTEDF LPLPTGFLQV PRGLTDLEIG MYALLGVFCL AILVFLINCI VFVLRYRHKR IPPEGQTSMD HSHHWVFLGN GQPLRVQGEL SPPAGNPLET VPAFCHGDHH SSGSSQTSVQ SQVHGRGDGS SGGSARDQAE DPASSPTSKR KRVKFTTFTT LPSEELAYDS VPAGEEDEEE EEDLGWGCPD VAGPTRPTAP PDLHNYMRRI KEIA
Explore Transmembrane protein 132E with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets